The Effects of Psychedelic Assisted Therapy on Sleep in Patients with Psychiatric Conditions: A Systematic Review

Abstract

Serotonergic agonists like psilocybin, MDMA and Ketamine may interact with sleep like other antidepressant drugs. The most consistent effects of SSRIs, TCAs, serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (MAOIs) have been reported on REM sleep in terms of reduced duration and increased latency, both after acute and chronic use. Because of its general safety, intermediate duration of action, and therapeutic potential in several neuropsychiatric disorders, psilocybin is currently the most intensely studied psychedelic in clinical trials. We are investigating the changes that occur during the sleep cycle after controlled treatment with psychedelic assisted therapy in patients with psychiatric related conditions. We hypothesize that the antidepressant properties of these substances will reduce rapid eye movement (REM) sleep and prolonged REM latency.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords